Fabrice Egros to assume Corporate Development responsibilities at Lupin; stock trades flat

23 Feb 2022 , 03:05 PM

Global pharma major, Lupin Limited (Lupin), in its press release today, announced changes to its executive team with assigning Global Corporate Development responsibilities to Dr. Fabrice Egros as President, Corporate Development and Growth Markets. Dr. Egros will step in the shoes of Alan Butcher departing from the Company on February 28, 2022.

Dr. Egros will overlook and guide the development and execution of the Company’s inorganic growth strategy, including mergers and acquisitions, business development, in-licensing arrangements, and related matters. He will continue to occupy his existing leadership position in LATAM and Asia regions in this new role.

“Company is thrilled to announce Fabrice taking over responsibilities for Corporate Development in addition to the Growth Markets business. With Fabrice’s leadership and exemplary success in growing Lupin’s business through both organic and inorganic initiatives, we are well positioned to deliver on our growth aspirations. We thank Alan for his contribution to our organization and wish him well for the future,” said Vinita Gupta, CEO, Lupin.

For the past over six years, Dr. Egros has played an integral role in Lupin, leading businesses across both Growth and Developed markets. His extensive cross-border experience will be an asset to Lupin in this new role.

At around 3.13 PM, Lupin was trading at Rs755.50 up by Rs3.35 or 0.45% from its previous closing of Rs752.15 on the BSE. The scrip opened at Rs758 and has touched a high and low of Rs763.15 and Rs755 respectively.